Azacitidine Kills Leukemia Cells Through RNA, Study Finds
A Molecular Cell study tracked azacitidine's first 24 hours in leukemia cells and found the killing runs through RNA methylation. The result names NSUN2 as a cleaner target, and it hasn't yet met a patient.
Twenty years of use. The mechanism just moved.
Azacitidine kills leukemia cells mainly through RNA in its first day, not through the DNA route textbooks assigned it.
The evidence is a cell study, not a patient trial. Boyang Gao and colleagues at the University of Chicago and UT Health San Antonio published the work in Molecular Cell, with Chuan He as senior author. Azacitidine has treated high-risk myelodysplastic syndromes and acute myeloid leukemia for more than two decades, and it helps only a third to half of patients. Doctors still can't predict who'll respond.
The team timed the drug's first 24 hours. Mass spectrometry showed levels of 5-methylcytosine, a chemical tag, dropping sharply on chromatin-associated RNA within eight hours, while DNA methylation didn't move across the full first day. The drug also bound directly to NSUN2, the enzyme that installs those RNA tags, and the binding peaked at the same eight-hour mark.
The comparison drug did the ruling out. Decitabine works only through slow DNA changes, and it had almost no effect on cell survival inside the same 24 hours. When the researchers depleted NSUN2 without any drug, the leukemia cells collapsed the same way: they stopped dividing, lost DNA repair and shut down the same genes. Depleting DNMT1, the main DNA-tagging enzyme, didn't reproduce the effect.
The limits are plain. Every result comes from leukemia cells in the lab, and the study doesn't show the RNA route driving outcomes in patients. The response markers are leads, not tests: cells carrying TET2 or IKZF1 mutations were especially sensitive to lost RNA methylation, but nobody has confirmed that split in a clinic.
The finding still rearranges two things. It explains why azacitidine pairs so well with venetoclax, since a drug that triggers cell death within hours complements one that pushes cells to self-destruct. And it hands drug hunters a narrower target. The team around He plans NSUN2 inhibitors, and his summary of the data is blunt: 'we know most of the azacitidine goes into RNA.'
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.